Go to content Go to the menu Go to the search

Quick access, personalized services
Centre d'Immunologie et des Maladies Infectieuses
UPMC UMRS CR7 - Inserm U1135 - CNRS ERL 8255

Platforms and Equipments

The Cimi has also developed internal platforms, dedicated to specific technological aspects related to the research activities carried out in the center.

  • Flow cytometry. The first Cimi investment was upgrading the flow cytometry systems used on a routine basis by many members of the Cimi Immunology teams. The Inserm largely contributed in expanding the number of flow cytometers at the Cimi with the purchase of a compact Biorad S3™ cell sorter, a BD LSRFortessa™ X-20 cell analyzer configured to detect up to 20 parameters simultaneously, and an ARIA cell sorter. This strong investment supports the ever increasing demands in multicolor flow cytometry and raises the park of cytometers to 4 analyzers and 2 cell sorters, all of which are now located in two dedicated flow cytometry areas and managed by two engineers (L. Papagano, Engineer UPMC and S. Gregoire, Engineer CNRS).
  • Single Molecule Array (SimoaTM) technology using an HD-1 Analyzer (Quanterix Corporation) is now available at the Cimi. It is a highly sensitive automated instrument that runs immunoassays. Cimi members collaborate with Quanterix R&D teams to design and optimize novel assays. The Cimi is currently setting up a partnership to develop an experimental show case with Quanterix Corporation.
  • a microfluidics platform (FluidigmTM) is available at the Cimi (Inserm investments), enabling cloning as well as single-cell gene expression analysis from single-cell samples using Fluidigm's Dynamic Array™ integrated fluidic circuits and the BioMark™ system for genetic analysis. Two technicians (from the CNRS, team B. Autran) and an associate professor (R. Zoorob) are devoted to these methods and have provided the Cimi’s partners advice and technical support.
  • a BSL2 insectarium was developed by Pr. D. Mazier, for in-site production of P. cynomolgi sporozoites.

 Some Cimi teams have also developed highly sought-after expertise that is now put forwards in a Technical “plateau” for public-private partnerships

  • The Human skin explant platform: Thanks to the “Fondation pour la Recherche Médicale” and EU funding, Behazine Combadiere’s team has developed expertise and technical tools for ex vivo investigation of human skin explants. The platform SkinSE (Skin Systems Evaluation) created in 2015 is unique in France. The objective is to offer academic and industrial scientists ex vivo human cells to support research. SkinSE aims to propose relevant and reliable ex vivo intact human skin and in vitro primary skin cells for pharmaceutical products (vaccines, chemicals, biomolecules, micro and nanoparticles), for decision-making during research and developmental phases. Screening tests can be used as alternatives to animal models in the process of product validation. SkinSE can provide expertise in the study of skin tissues and cells using up-to-date technology such as omics analysis (proteome, transcriptome, immune responses, cytokine secretion, cellular phenotype). SkinSE aims to develop its activities, and its biological collection of skin and blood samples reflecting different allergies and infectious diseases. A few contractual collaborations have been obtained with academics and industrials.
  • Guy Gorochov’s team has adapted flow cytometry protocols to bacteria and microbiota phenotyping, and cell sorting and has also established quality assessment tools for metagenomic analysis of small clinical samples. We have established in collaboration with E. Slack and A. MacPherson (Zürich, Bern, CH), a combined bacterial flow cytometry and sequencing platform to detail antibody-opsonized bacteria at metagenomic level (Nature Protocols 2016).
  • O. Silvie’s team has set-up a transgenesis plateau for the genetic manipulation of malaria parasites. They have developed specific vectors, protocols and transgenic Plasmodium lines that are shared with external research groups.

Interactions with core facilities of Service Units (UMS)

 For the past ten years, Cimi team members (from the previous IFR113 and the current Cimi) have played a major role in the creation and/or development of core facilities that are now integrated into the UMS service units created in 2014. These core facilities include:

  •  an up-to-date SPF-free animal facility (“NAC” with Drs. B. Salomon and B. Combadière as board members) (UMS28)
  • a “Humanized mice” platform (“SHUPS”) (Drs. G. Marodon and B. Combadière as scientific officers), (UMS28)
  • a Flow Cytometry platform (“CyPS”) (Prs B Autran, F Lemoine as board members), (UMS 30 LUMIC)
  • a Proteomic platform in P3S (initiated by D. Mazier; O. Silvie currently scientific officer), (UMS 29 Omique)

 The Cimi has been very much committed to managing and improving these facilities. As an example, the CyPS platform is now equipped with a CyTOF-Mass Cytometer, a new generation cytometer that can enable highly multi-parametric single cell analysis, which was acquired with funds from the Cimi. The P3S proteomic facility will acquire a new LC-MS/MS system (700 k€), and the Cimi contributed to the funding of this new equipment. The recent emergence of multi-photon imaging in immunology has given new insights to ancient immunological concepts. The Cimi, in partnership with the “Centre d’Expérimentation Fonctionnelle” or CEF animal facility, recently acquired a state-of the-art multiphoton microscope (ZeissTM) that provides multimodal non-linear optical imaging (ie multiphoton excitation fluorescence, secondary and tertiary harmonics as well as coherent anti-stoke Raman scattering). It enables the observation of cell motility, certain cell functions in real time and in the cells’ physiological environment. A. Boissonnas is the current scientific officer of this platform. The funding for this platform raised by the Cimi (C. Combadiere) and the CEF (S. Morosan) was of 640 k€, counting 66% from the “Région Ile de France DIM MALINF”.


Traductions :


cimi-paris @ upmc.fr